Heparin Sodium
Injection · trading as Heparin Sodium In Sodium Chloride
Current
FDA shortage record
- Substance
- Heparin Sodium
- Brand name
- Heparin Sodium In Sodium Chloride
- Manufacturer
- Baxter Healthcare Corporation
- Dosage form
- Injection
- Presentation
- Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)
- Route(s)
- INTRAVENOUS
- Therapeutic category
- Hematology
- Package NDC
0338-0433-04- Initially posted
- 11/14/2017
- Current FDA status
- Current
Reason and context
Reason reported: Shortage of an inactive ingredient component
Estimated recovery: May 2026
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 888-229-0001.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
0d929726-76c3-48fc-b4e7-fd06409f9fb3). - FDA UNII identifier:
ZZ45AB24CA. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.